Industry
Medical - Diagnostics & Research
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Loading...
Open
123.17
Mkt cap
15B
Volume
1M
High
123.97
P/E Ratio
58.32
52-wk high
129.50
Low
119.03
Div yield
0.00
52-wk low
82.17
Portfolio Pulse from Piero Cingari
July 29, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 10:47 am
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 10:05 am
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 10:01 am
Portfolio Pulse from Benzinga Newsdesk
July 08, 2024 | 10:43 am
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 3:56 pm
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 4:08 pm
Portfolio Pulse from Benzinga Insights
April 30, 2024 | 4:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.